AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Senseonics Holdings, Inc.
Video analysis: SENS
All videosNo video analysis for this stock yet. Request one from our team.
News: SENS
Senseonics Announces Strategic Partnership with Beta Bionics to Integrate Eversense® 365 with the iLet® Bionic Pancreas
Pairing year-long continuous glucose monitoring with automated insulin delivery to further simplify diabetes management for patients Brings Eversense 365 to the growing community of iLet Bionic Pancreas users Plan for commercial launch of the integrated system in Q4 2026 GERMANTOWN, Md., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS), maker of the Eversense 365 Continuous Glucose Monitoring (CGM) System, the world's first and only long-term, one-year implantable sensing technology, today announced a partnership with Beta Bionics, Inc (NASDAQ: BBNX), a pioneering leader in the development of advanced diabetes management solutions.
Senseonics To Participate in Upcoming Institutional Investor Conferences
GERMANTOWN, Md., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to participate in two upcoming investor conferences.
BlackRock Inc. Makes New Investment in Senseonics Holdings, Inc. Common Stock $SENS
BlackRock Inc. bought a new stake in Senseonics Holdings, Inc. Common Stock (NASDAQ: SENS) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 2,793,558 shares of the company's stock, valued at approximately $15,867,000. BlackRock Inc. owned approximately 6.68% of Senseonics Holdings,
Senseonics Holdings, Inc. Common Stock Q2 Earnings Call Highlights
Senseonics Holdings, Inc. Common Stock NASDAQ: SENS raised its full-year 2026 revenue and gross-margin outlook after reporting second-quarter revenue growth of approximately 120% and its highest organic gross margin to date.
Senseonics Holdings, Inc. (SENS) Q2 2026 Earnings Call Transcript
Senseonics Holdings, Inc. (SENS) Q2 2026 Earnings Call Transcript
Senseonics Holdings (SENS) Reports Q2 Loss, Tops Revenue Estimates
Senseonics Holdings (SENS) came out with a quarterly loss of $0.63 per share versus the Zacks Consensus Estimate of a loss of $0.55. This compares to a loss of $0.4 per share a year ago.
Senseonics Holdings, Inc. Schedules Second Quarter 2026 Earnings Release and Conference Call for August 6, 2026 at 4:30 P.M. Eastern Time
GERMANTOWN, Md., July 21, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS) a medical technology company focused on implantable Continuous Glucose Monitoring (CGM) Systems for people with diabetes, today announced that it plans to release its second quarter 2026 financial results after market close on Thursday, August 6, 2026.
Strength Seen in Senseonics (SENS): Can Its 6.1% Jump Turn into More Strength?
Senseonics (SENS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
